CoChat
Sign Up
Cited by 107Antifungal resistance and susceptibilityFungal Infections and StudiesYeasts and Rust Fungi Studies

Comparison of in vivo pathogenicity of four Candida auris clades in a neutropenic bloodstream infection murine model

Open access
Forgács, Lajos, Borman, Andrew M., Prépost, Eszter, Tóth, Zoltán, Kardos, Gábor, Kovács, Renátó, Szekely, Adrien, Nagy, Fruzsina +2 more·2020·Emerging Microbes & Infections
DOI 10.1080/22221751.2020.1771218PMC PMC7448943
Open this paper in CoChat — free accountOpen PDF

Abstract

Candida auris is an emerging worldwide concern, but comparative data about the virulence of different C. auris lineages in mammalian hosts is lacking. Different isolates of the four prevalent C. auris clades (South Asian n = 5, East Asian n = 4, South African n = 5, and South American n = 5) were compared to assess their virulence in a neutropenic murine bloodstream infection model with C. albicans as reference. C. auris, regardless of clade, proved to be less virulent than C. albicans. Highest overall mortality at day 21 was observed for the South American clade (96%), followed by the South Asian (80%), South African (45%) and East Asian (44%) clades. Fungal burden results showed close correlation with lethality. Histopathological examination revealed large aggregates of blastoconidia and budding yeast cells in the hearts, kidneys and livers but not in the spleens. The myocardium of apparently healthy sacrificed mice as well as of mice found moribund showed contraction band necrosis in case of all lineages. Regardless of clade, the heart and kidneys were the most heavily affected organs. Isolates of the same clade showed differences in virulence in mice, but a markedly higher virulence of the South American clade was clearly demonstrated.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/22221751.2020.1771218

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. [1]Satoh K, Makimura K, Hasumi Y, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009; 53: 41– 44. doi: 10.1111/j.1348-0421.2008.00083.x 19161556 · DOI · Paper page
  2. [2]Lee WG, Shin JH, Uh J, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011; 49: 3139– 3142. doi: 10.1128/JCM.00319-11 21715586 PMC3165631 · DOI
  3. [3]Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2016; 64: 134– 140. doi: 10.1093/cid/ciw691 27988485 PMC5215215 · DOI · Paper page
  4. [4]Sekyere J O. Candida auris: a systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. MicrobiologyOpen. 2018; 7: e578, doi: 10.1002/mbo3.578. PMC6079168 29345117 · DOI
  5. [5]Armstrong PA, Rivera SM, Escandon P, et al. Hospital-associated multicenter outbreak of emerging fungus Candida auris, Colombia, 2016. Emerg Infect Dis. 2019; 25: 1339– 1346. doi: 10.3201/eid2507.180491 31211679 PMC6590770 · DOI
  6. [6]Rudramurthy SM, Chakrabarti A, Paul RA, et al. Candida auris candidaemia in Indian ICUs: analysis of risk factors. J Antimicrob Chemother. 2017; 72: 1794– 1801. doi: 10.1093/jac/dkx034 28333181 · DOI · Paper page
  7. [7]Chowdhary A, Prakash A, Sharma C, et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018; 73: 891– 899. doi: 10.1093/jac/dkx480 29325167 · DOI · Paper page
  8. [8]Chow NA, de Groot T, Badali H, et al. Potential fifth clade of Candida auris, Iran, 2018. Emerg Infect Dis. 2019; 25: 1780– 1781. doi: 10.3201/eid2509.190686 31310230 PMC6711235 · DOI · Paper page
  9. [9]Szekely A, Borman AM, Johnson EM. Candida auris isolates of the Southern Asian and South African lineages exhibit different phenotypic and antifungal susceptibility profiles in vitro. J Clin Microbiol. 2019; 57(5). pii: e02055-18. doi: 10.1128/JCM.02055-18 PMC6498034 30867237 · DOI · Paper page
  10. [10]Borman AM, Szekely A, Johnson EM. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen, Candida auris and other key pathogenic Candida species. mSphere. 2016; 18: e00189– 16. PMC4990711 27547827
  11. [11]Alfouzan W, Dhar R, Albarrag A, et al. The emerging pathogen Candida auris: A focus on the Middle-Eastern countries. J Infect Public Health. 2019; 12: 451– 459. doi: 10.1016/j.jiph.2019.03.009 31000491 · DOI
  12. [12]Fakhim H, Vaezi A, Dannaoui E, et al. Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model. Mycoses. 2018; 61: 377– 382. doi: 10.1111/myc.12754 29460345 · DOI
  13. [13]Wang X, Bing J, Zheng Q, et al. The first isolate of Candida auris in China: clinical and biological aspects. Emerg Microbes Infect. 2018; 7: 93. 29777096 PMC5959928
  14. [14]Ben-Ami R, Berman J, Novikov A, et al. Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 2017; 23: 195– 203. doi: 10.3201/eid2302.161486 28098529 PMC5324804 · DOI · Paper page
  15. [15]Torres SR, Pichowicz A, Torres-Velez F, et al. Impact of Candida auris infection in a neutropenic murine model. Antimicrob Agents Chemother. 2020; 64(3). pii: e01625-19. doi: 10.1128/AAC.37.3.491 PMC7038241 31818824 · DOI
  16. [16]Singh S, Uppuluri P, Mamouei Z, et al. The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection. PLoS Pathog. 2019; 15(8): e1007460. doi: 10.1371/journal.ppat.1007460 31381597 PMC6695204 · DOI · Paper page
  17. [17]Xin H, Mohiuddin F, Tran J, et al. Experimental mouse models of disseminated Candida auris infection. mSphere. 2019; 4(5). pii: e00339-19. doi: 10.1128/mSphere.00339-19 PMC6731527 31484737 · DOI · Paper page
  18. [18]Prépost E, Tóth Z, Perlin DS, et al. Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against Candida albicans and Candida dubliniensis. Infect Drug Resist. 2019; 12: 1805– 1814. doi: 10.2147/IDR.S198764 31303773 PMC6612285 · DOI
  19. [19]Hopster DJ, Milroy CM, Burns J, et al. Necropsy study of the association between sudden cardiac death, cardiac isoenzymes and contraction band necrosis. J Clin Pathol. 1996; 49: 403– 406. doi: 10.1136/jcp.49.5.403 8707956 PMC500481 · DOI
  20. [20]Morales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, et al. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis. 2017; 23: 162– 164. doi: 10.3201/eid2301.161497 27983941 PMC5176232 · DOI
  21. [22]Vallabhaneni S, Kallen A, Tsay S, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus-United States, May 2013-August 2016. Am J Transplant. 2017; 17: 296– 299. doi: 10.1111/ajt.14121 28029734 · DOI · Paper page
  22. [23]Ruiz-Gaitán A, Moret AM, Tasias-Pitarch M, et al. An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses. 2018; 61: 498– 505. doi: 10.1111/myc.12781 29655180 · DOI · Paper page
  23. [24]Johnson CJ, Davis JM, Huttenlocher A, et al. Emerging fungal pathogen Candida auris evades neutrophil attack. mBio. 2018; 9i: e01403– 18. PMC6106086 30131360
  24. [25]Chowdhary A, Sharma C, Duggal S, et al. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis. 2013; 19: 1670– 1673. doi: 10.3201/eid1910.130393 24048006 PMC3810747 · DOI
  25. [26]Araúz AB, Caceres DH, Santiago E, et al. Isolation of Candida auris from 9 patients in Central America: Importance of accurate diagnosis and susceptibility testing. Mycoses. 2018; 61: 44– 47. doi: 10.1111/myc.12709 28945325 · DOI
  26. [27]Al Maani A, Paul H, Al-Rashdi A, et al. Ongoing challenges with healthcare-associated Candida auris outbreaks in Oman. J Fungi (Basel). 2019; 23; 5(4). pii: E101. PMC6958405 31652825

Cited by

Sorted by citations

Authors
Forgács, L., Borman, A. M., Prépost, E., Tóth, Z., Kardos, G., Kovács, R., Szekely, A., Nagy, F., Kovacs, I., & Majoros, L.
Affiliations
  • University of Debrecen (HU)
  • Public Health England (GB)
  • UK National Mycology Reference Laboratory (MRL), Public Health England South-West
Corresponding author
Majoros, László
ORCID
Venue
Emerging Microbes & Infections
Publisher
Informa UK Limited
Published
2020-01
Volume
9
Issue
1
Pages
1160-1169
ISSN
2222-1751 (ISSN-L)
DOI
10.1080/22221751.2020.1771218
PMC
PMC7448943
OpenAlex
W3031864352
Cited by
107
References
2
Citations by year
2026: 20 · 2025: 15 · 2024: 22 · 2023: 19 · 2022: 12 · 2021: 13 · 2020: 6
FWCI
1.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Emerging Microbes & Infections (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
European Social Fund
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Yeasts and Rust Fungi Studies
Keywords
Candida auris, clades, virulence, mouse model, Candida albicans, fungal burden, histopathology, myocardial necrosis, mortality
MeSH terms
Animals, Antifungal Agents, Candida, Candida albicans, Disease Models, Animal, Heart, Kidney, Male, Mice, Inbred BALB C, Necrosis, Neutropenia, Virulence, Mice, Candidemia, Bacterial Load

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review